GlaxoSmithKline completes Sirtris Pharmaceuticals deal
GlaxoSmithKline (GSK) has completed its acquisition of US-based Sirtris Pharmaceuticals for approximately US$720m (
GlaxoSmithKline (GSK) has completed its acquisition of US-based Sirtris Pharmaceuticals for approximately US$720m (£362m) through a cash tender offer of $22.50 (£11.33) per share.
The purchase will significantly enhance GSKs research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process.
Sirtris will become part of GSK's Drug Discovery organisation, while continuing to operate from laboratories in Cambridge, Massachusetts as an autonomous drug discovery unit.
Christoph Westphal, ceo and vice chair of Sirtris, and the management team will continue to lead this autonomous unit.